Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
Pharmaworks (a ProMach company) appointed Nathan Allen as Vice President and General Manager.
read more
The pharmaceutical equipment market size will grow by $5.454B from 2022 to 2027, a report by Technavio anticipates. In addition, the market will increase at a CAGR of 6.67% during the forecast period.
read more
The global market for fertility supplements will grow at a CAGR of about 8% by 2028, according to a report from Delveinsight Business Research.
read more
The global dietary supplements market is projected to grow at a CAGR of 7.29% from 2022 to 2030, according to a report by Verified Market Research®. The report valued the marketat $129.76B in 2021 and projects it to reach $239.50B by the end of the forecast period.
read more
The global excipients market is projected to reach $13.05B by 2030, at a CAGR of 4.03%, according to a report by Research & Markets.
read more
The global pharmaceutical manufacturing market, rising at a CAGR) of 7.63% is projected to be valued at $929.9B by 2030, according to a report by Research & Markets.
read more
Patients and caregivers value calendarized adherence packaging and believe it improves personalization, according to a study commissioned by Covectra, a company that offers serialization and anti-counterfeiting methods.
read more
AstraZeneca and Merck announced that LYNPARZA in combination with abiraterone and prednisone or prednisolone (abi/pred) has been approved in Japan for the treatment of adult patients with BRCA-mutated (BRCAm) castration-resistant prostate cancer with distant metastasis (mCRPC).
read more
European product recalls continued to increase across five key industries in the second quarter of 2023, rising 7.8% from the previous quarter.
read more
Phathom Pharmaceuticals, which focuses on developing and commercializing treatments for gastrointestinal diseases, announced it has submitted to the FDA six-month stability data from its long-term and accelerated stability program for its reformulated vonoprazan tablets.
read more
The U.S. Food and Drug Administration (FDA) has approved Sohonos (palovarotene) capsules for reduction in the volume of new heterotopic ossification (extra-skeletal bone formation) in adults and children aged 8 years and older for females, and 10 years and older for males with fibrodysplasia ossificans progressiva.
read more
Upsher-Smith announced the recent launch of Mesalamine extended-release Capsules, USP 375 mg.
read more
The U.S. Food and Drug Administration (FDA) has approved INGREZZA® (valbenazine) capsules for the treatment of adults with chorea associated with Huntington's disease (HD).INGREZZA, by Neurocrine Biosciences, is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor.
read more
The pharmaceutical packaging market size is expected to grow by $48,889.6M during 2022-2027, expanding at a CAGR of 8.44%, according to a report by Technavio.
read more
The US pet supplements market was valued at $890M in 2022 and is expected to reach
$1.38B by 2028, growing at a CAGR of 7.60% during the forecast period, according to a report from Research & Markets.
read more